|Mr. Habib J. Dable||CEO, Pres & Director||1.02M||N/A||1969|
|Dr. Thomas P. Maniatis||Co-Founder, Member of Scientific Advisory Board & Director Emeritus||22.5k||N/A||1943|
|Mr. Kevin F. McLaughlin||Sr. VP, CFO & Treasurer||603.93k||N/A||1956|
|Dr. Ravindra Kumar||Chief Scientific Officer & Sr. VP||543.06k||N/A||1960|
|Mr. Sujay R. Kango||Exec. VP & Chief Commercial Officer||595.54k||N/A||1964|
|Dr. Mark Ptashne||Co-Founder and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Ms. Lisa Wyman||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Mr. Todd James IRC||Sr. VP of Corp. Affairs & Investor Relations||N/A||N/A||N/A|
|Mr. Adam M. Veness Esq.||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||1986|
|Mr. Matthew S. Fearer||Director of Corp. Communications||N/A||N/A||1966|
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Acceleron Pharma Inc.’s ISS Governance QualityScore as of November 1, 2019 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 6; Compensation: 7.